Pelacarsen reduces Lp(a) levels but not CV outcomes

Full results of the Phase 3 Lp(a) HORIZON trial, presented at a late breaker session of AHA Scientific Sessions, showed that, while pelacarsen reduced Lp(a) levels by 78% in adults with elevated Lp(a) and established cardiovascular disease (CVD), there was no change in primary endpoint (time to nonfatal heart attack, stroke, urgent revascularisation, death from any cardiovascular (CV) cause, death from coronary heart disease or death from any cause).^1,2